Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation.
Oran
B
B
Giralt
S
S
Couriel
D
D
Hosing
C
C
Shpall
E J
EJ
de Meis
E
E
Khouri
I F
IF
Qazilbash
M
M
Anderlini
P
P
Kebriaei
P
P
Popat
U
U
Carrasco-Yalan
A
A
Champlin
R E
RE
de Lima
M
M
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000706:statistics & numerical data; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D017710:Lymphocyte Transfusion / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000008:administration & dosage; D009190:Myelodysplastic Syndromes / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D010166:Palliative Care; D012008:Recurrence; D012074:Remission Induction; D016879:Salvage Therapy; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous
D007166:Immunosuppressive Agents; D019653:Myeloablative Agonists